A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Eli Lilly and Company
Eli Lilly and Company
Canadian Cancer Trials Group
Masonic Cancer Center, University of Minnesota
Northwestern University
Altor BioScience
National Institutes of Health Clinical Center (CC)